

# Sulfonimide and Amide Derivatives as Novel PPAR $\alpha$ Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies

Alessandra Ammazalorso,\* Isabella Bruno, Rosalba Florio, Laura De Lellis, Antonio Laghezza, Carmen Cerchia, Barbara De Filippis, Marialuigia Fantacuzzi, Letizia Giampietro, Cristina Maccallini, Paolo Tortorella, Serena Veschi, Fulvio Loiodice, Antonio Lavecchia, Alessandro Cama, and Rosa Amoroso

Cite This: *ACS Med. Chem. Lett.* 2020, 11, 624–632


Read Online

ACCESS |

Metrics & More

Article Recommendations

Supporting Information



**ABSTRACT:** An agonist–antagonist switching strategy was performed to discover novel PPAR $\alpha$  antagonists. Phenylidiazanyl derivatives of fibrates were developed, bearing sulfonimide or amide functional groups. A second series of compounds was synthesized, replacing the phenylidiazanyl moiety with amide or urea portions. Final compounds were screened by transactivation assay, showing good PPAR $\alpha$  antagonism and selectivity at submicromolar concentrations. When tested in cancer cell models expressing PPAR $\alpha$ , selected derivatives induced marked effects on cell viability. Notably, 3c, 3d, and 10e displayed remarkable antiproliferative effects in two paraganglioma cell lines, with CC<sub>50</sub> lower than commercial PPAR $\alpha$  antagonist GW6471 and a negligible toxicity on normal fibroblast cells. Docking studies were also performed to elucidate the binding mode of these compounds and to help interpretation of SAR data.

**KEYWORDS:** PPARs, sulfonimide, amide, antagonist, phenylidiazanyl, cytotoxicity

Since the discovery of Peroxisome Proliferator-Activated Receptors (PPARs), a large body of knowledge about these nuclear receptors has been collected to date.<sup>1</sup> PPARs control important metabolic functions in the body, mainly implicated in lipid and glucose homeostasis, insulin sensitivity, and energetic metabolism, through the activation of three subtypes, namely PPAR $\alpha$ , PPAR $\gamma$ , and PPAR $\delta$ .<sup>2</sup> PPAR $\alpha$  and PPAR $\gamma$  agonists are currently marketed to treat metabolic disorders, such as hyperlipidemias, hypertriglyceridemias, and type 2 diabetes. PPAR $\alpha$  agonists, such as fibrates, represent therapeutic options useful to decrease lipoprotein and triglyceride levels,<sup>3,4</sup> whereas PPAR $\gamma$  agonists thiazolidinediones (TZDs) improve insulin sensitivity in type 2 diabetes and in metabolic disorders as obesity, dyslipidemia, and metabolic syndrome.<sup>5</sup> However, a moderate activation of PPARs has been emerging as a novel therapeutic opportunity to contrast metabolic disorders; partial agonists, inverse agonists, and antagonists have been synthesized to investigate

the pharmacological actions obtained by a reduced activation of PPARs. Several PPAR antagonists have been described,<sup>6</sup> together with molecular mechanisms implicated in the PPAR repression. While some antagonists were identified by a random screening, many of these compounds have been obtained by chemical manipulation of known agonists, according to the helix12-folding inhibition hypothesis proposed by Hashimoto.<sup>7</sup>

A reduced PPAR $\alpha$  activity has been shown to be beneficial in different types of cancer, where a metabolic switch from

**Special Issue:** In Memory of Maurizio Botta: His Vision of Medicinal Chemistry

**Received:** December 30, 2019

**Accepted:** March 3, 2020

**Published:** March 3, 2020



glucose to fatty acid oxidation (FAO) metabolism occurs. Some tumors, including leukemia, prostate, ovarian, and renal cell carcinomas, are strongly dependent on FAO for survival and proliferation.<sup>8</sup> PPAR $\alpha$  antagonists showed antitumor effects in different cancer cell lines,<sup>9</sup> as chronic lymphocytic leukemia,<sup>10</sup> renal cell carcinoma,<sup>11</sup> glioblastoma,<sup>12</sup> colorectal and pancreatic cancer,<sup>13</sup> and paraganglioma.<sup>14,15</sup>


In the search for novel PPAR antagonists, in this work we describe an agonist–antagonist switching design. The modification of the carboxylic head of PPAR $\alpha$  agonists has been proven to be a successful strategy to obtain antagonists: we reported in previous works the discovery of sulfonimide derivatives of fibrates, showing antagonistic properties on PPAR $\alpha$ .<sup>16,17</sup> In previous studies, we synthesized novel PPAR agonists, based on a clofibrate or gemfibrozil skeleton.<sup>18,19</sup> Some of these derivatives showed good PPAR activation, with submicromolar potency. We selected the stilbene derivative (Lead compound I) and the phenyldiazenyl derivative (Lead compound II) as starting compounds to obtain the corresponding methyl and phenyl sulfonimide derivatives 1a–b and 2a–b (Figure 1), in the attempt to switch the

pharmacological behavior from agonists to antagonists. Lead compound I is a selective PPAR $\alpha$  agonist ( $EC_{50}$  1.0  $\mu$ M), whereas Lead compound II is a dual PPAR $\alpha/\gamma$  agonist, with a higher PPAR $\alpha$  efficacy and submicromolar potency ( $EC_{50}$  PPAR $\alpha$  0.6  $\mu$ M, PPAR $\gamma$  1.4  $\mu$ M).

Lead compounds I and II were obtained as previously described.<sup>18,19</sup> Carboxylic acids were transformed in sulfonimide derivatives 1a–b and 2a–b by treatment with methane- or benzenesulfonamide, 1-ethyl-3-(3-(dimethylamino)propyl)-carbodiimide (EDC), and 4-dimethylaminopyridine (DMAP) (Figure 1).

These compounds were evaluated for agonist activity on the human PPAR $\alpha$  (hPPAR $\alpha$ ) (Table 1) and PPAR $\gamma$  (hPPAR $\gamma$ ) subtypes (data not shown). For this purpose, GAL-4 PPAR chimeric receptors were expressed in transiently transfected HepG2 cells according to a previously reported procedure.<sup>20,21</sup> Due to cytotoxicity exhibited by these compounds on HepG2 cells above 5  $\mu$ M, their activity was evaluated at only three concentrations (1, 2.5, and 5  $\mu$ M) and compared with that of the corresponding reference agonists (Wy-14,643 for PPAR $\alpha$  and Rosiglitazone for PPAR $\gamma$ ) (Supporting Information, Figure S1) whose maximum induction was defined as 100%. Only 1a–b and 2a showed a weak selective activity toward PPAR $\alpha$  in the concentration range taken into consideration ( $E_{max}$  17–29%), whereas no activity was observed on PPAR $\gamma$  (data not shown). Given that 2b had no detectable PPAR $\alpha/\gamma$  activity, it was tested as an antagonist by conducting a competitive binding assay in which PPAR $\alpha$  and PPAR $\gamma$  activity at a fixed concentration of the reference agonists Wy-14,643 and Rosiglitazone, respectively, was measured in cells treated with increasing concentrations of 2b. Compound 2b completely inhibited PPAR $\alpha$  activity with a half-maximal inhibitory concentration of  $1.2 \pm 0.1$   $\mu$ M showing also a simultaneous inhibition of PPAR $\gamma$  even though with lower potency and activity ( $IC_{50}$   $14 \pm 2$   $\mu$ M;  $I_{max}$  87%).

Based on these results, phenyldiazenyl compound 2b was selected as a novel scaffold to develop novel compounds by designing the benzenesulfonimide and amide derivatives displayed in Figure 2. In sulfonimide derivatives 3a–g, with the aim of probing further binding interactions inside the ligand binding domain (LBD), we introduced groups with




**Figure 1.** From Lead compounds I and II to sulfonimide derivatives 1a–b and 2a–b. Reagents and conditions: methane- (a) or benzenesulfonamide (b), EDC, DMAP, dry dichloromethane, 0 °C–rt, 24 h, yield 44–65%.

**Table 1.** hPPAR $\alpha$  Activity by GAL-4 PPAR Transactivation Assay for Synthesized Compounds<sup>a</sup>

ID	hPPAR $\alpha$			ID	hPPAR $\alpha$		
	$E_{max}$ %	$I_{max}$ %	$IC_{50}$ $\mu$ M		$E_{max}$ %	$I_{max}$ %	$IC_{50}$ $\mu$ M
1a	17 $\pm$ 6	–	–	4c	32 $\pm$ 7	–	–
1b	24 $\pm$ 6	–	–	4d	i	96 $\pm$ 4	2.72 $\pm$ 0.85
2a	29 $\pm$ 6	–	–	10a	24 $\pm$ 2	78 $\pm$ 2	7.0 $\pm$ 1.7
2b	i	99 $\pm$ 1	1.2 $\pm$ 0.1	10b	28 $\pm$ 3	12 $\pm$ 1	–
3a	i	100 $\pm$ 1	0.17 $\pm$ 0.12	10c	28 $\pm$ 2	62 $\pm$ 7	12.3 $\pm$ 0.9
3b	i	99 $\pm$ 1	0.33 $\pm$ 0.14	10d	12 $\pm$ 1	71 $\pm$ 2	12.1 $\pm$ 1.1
3c	i	100 $\pm$ 1	0.21 $\pm$ 0.13	10e	i	100 $\pm$ 1	0.24 $\pm$ 0.04
3d	i	92 $\pm$ 1	1.1 $\pm$ 0.7	13a	i	93 $\pm$ 6	3.32 $\pm$ 1.31
3e	i	100 $\pm$ 1	1.5 $\pm$ 0.5	13b	i	87 $\pm$ 4	1.70 $\pm$ 0.25
3f	i	88 $\pm$ 3	2.8 $\pm$ 0.7	13c	21 $\pm$ 1	67 $\pm$ 3	6.1 $\pm$ 0.8
3g	i	69 $\pm$ 10	3.20 $\pm$ 0.44	13d	i	94 $\pm$ 4	10.3 $\pm$ 2.7
4a	i	94 $\pm$ 4	2.98 $\pm$ 1.02	13e	i	100 $\pm$ 5	1.52 $\pm$ 0.22
4b	12.0 $\pm$ 0.3	95 $\pm$ 6	2.67 $\pm$ 1.15				

<sup>a</sup>i = activity below 5% at the highest tested concentration.  $E_{max}$ % represents the percentage of maximum fold induction obtained with PPAR $\alpha$  agonist Wy-14,643, taken as 100%.  $I_{max}$ % represents the percentage of inhibition of the maximum effect obtained with the reference agonist Wy-14,643.



**Figure 2.** Chemical structures of final compounds **3a–g**, **4a–d**, **10a–e**, and **13a–e**.

different stereoelectronic properties in the *para* position, including hindered substituents containing an additional aromatic ring. As amide derivatives, we selected first the primary amide **4a** and the butyl, phenyl, and benzyl secondary amides **4b–d**. Next, a second series of compounds (**Figure 2**) was developed by replacing the azo moiety with amide or urea. Designed compounds were primary and secondary amides (**10a–d** and **13a–d**) and benzenesulfonimide derivatives (**10e** and **13e**).

The synthesis of benzenesulfonimides **3a–g** and of amides **4a–d** was performed starting from Lead compound II. Sulfonimides **3a–g** were obtained by direct coupling of starting carboxylic acid with proper *para*-substituted phenylsulfonamides, with EDC and DMAP, in dry CH<sub>2</sub>Cl<sub>2</sub> (**Scheme 1**). For compounds **3e–g**, the *p*-substituted phenylsulfonamides were synthesized as previously reported.<sup>22</sup> Amides **4b–d** were synthesized by coupling Lead compound II with proper amines, *N,N'*-dicyclohexylcarbodiimide (DCC), 1-hydroxybenzotriazole hydrate (HOBT), and *N*-methylmorpholine (NMM) in DMF. For derivative **4a**, the starting acid was reacted with ammonium chloride, under the conditions described.

Final products **10a–e** and **13a–e** were obtained as depicted in **Scheme 2**. Phenol **5** was synthesized by reacting *p*-aminophenol with benzoyl chloride, in the presence of triethylamine (TEA) in dry DMF, whereas the reaction of *p*-aminophenol with phenylisocyanate, in dry acetonitrile,

afforded phenol **6**. Both phenols **5** and **6** were reacted with intermediate ester **7**, synthesized by reaction of 4-(2-hydroxyethyl)phenol with ethyl 2-bromoisobutyrate.

The Mitsunobu coupling of phenols **5** and **6** with ester **7** produced **8** and **11**, which were hydrolyzed in basic conditions to acids **9** and **12**. Final amides and sulfonimides **10a–e** and **13a–e** were obtained as previously described for compounds **3a–g** and **4a–d**.

All these compounds were evaluated for agonist activity on hPPAR $\alpha$  (**Table 1**) and hPPAR $\gamma$  (data not shown) at different concentrations in the range 1–25  $\mu$ M. Most compounds were either poorly active or inactive on both PPAR subtypes; thus, they were tested as antagonists, as reported above. Overall, tested compounds were completely inactive on PPAR $\gamma$  (data not shown).


Sulfonimides **3a–g** showed a selective good antagonist profile on PPAR $\alpha$ , with displacement activity toward reference compound Wy-14,643 ranging from 69% to 100%. The IC<sub>50</sub> calculated for these compounds displayed a low micromolar potency, with being **3a**, **3b**, and **3c** the most potent compounds (IC<sub>50</sub> 0.17, 0.33, and 0.21  $\mu$ M, respectively). The increased steric hindrance in the *para* position by introduction of an additional aromatic ring (**3f** and **3g**) decreased the antagonist activity (IC<sub>50</sub> 2.8 and 3.2  $\mu$ M, respectively).

As regards amides **4a–d**, they were also able to selectively antagonize PPAR $\alpha$  exhibiting good efficacy (94–96%) and micromolar potency (2.67–2.98  $\mu$ M). Only compound **4c** was not tested as PPAR $\alpha$  antagonist due to its residual activity ( $E_{\max}$  32%) on this receptor subtype. The two series of compounds developed by replacing the azo moiety with amide and urea exhibited similar behavior even though with small but significant differences. All these compounds showed selective and moderate ability to antagonize PPAR $\alpha$ , with ureido derivatives **13a–d** being more effective and potent compared to corresponding amides **10a–d**.


Among compounds **10a–e** and **13a–e**, the two benzenesulfonimide derivatives **10e** and **13e** turned out to be the best PPAR $\alpha$  antagonists, being able to completely abolish the activation promoted by the reference agonist Wy-14,643. In this case, **10e** showed higher potency than **13e** (0.24 vs 1.52  $\mu$ M).

Considering that **3a–e**, **10e**, and **13e** appeared as the most promising compounds in transactivation assay, showing a PPAR $\alpha$  antagonist activity ranging from 92% to 100%, together with a potency in terms of IC<sub>50</sub> values ranging from 0.17 to

**Scheme 1.** Synthesis of Compounds **3a–g** and **4a–d**<sup>a</sup>



<sup>a</sup>Reagents and conditions: (a) *p*-substituted benzenesulfonamide, EDC, DMAP, dry CH<sub>2</sub>Cl<sub>2</sub>, N<sub>2</sub>, 0 °C–rt, 24 h, yield 21–80%; (b) R–NH<sub>2</sub>, DCC, HOBT, NMM, DMF, rt, 24 h, yield 67–90%.


Scheme 2. Synthesis of Compounds 10a–e and 13a–e<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) benzoyl chloride, TEA, dry DMF, N<sub>2</sub>, 0 °C–rt, 24 h, yield 70%; (b) phenylisocyanate, dry ACN, N<sub>2</sub>, reflux, 5h, yield 65%; (c) 7, PPh<sub>3</sub>, DIAD (diisopropyl azodicarboxylate), dry THF, 24 h, yield 54–97%; (d) 2 N NaOH, THF, reflux, 16 h, yield 57–63%; (e) R–NH<sub>2</sub>, DCC, HOBT, NMM, DMF, rt, 24 h, yield 29–98% (for amides 10a–d and 13a–d); benzenesulfonamide, EDC, DMAP, dry CH<sub>2</sub>Cl<sub>2</sub>, N<sub>2</sub>, 0 °C–rt, 24 h, yield 34–64% (for sulfonimides 10e and 13e); (f) ethyl 2-bromoisobutyrate, K<sub>2</sub>CO<sub>3</sub>, DMF, reflux, 4 h, yield 75%.

1.52 μM, we selected these compounds to perform gene expression analysis. We analyzed whether 3a–e, 10e, and 13e could modulate the expression of the PPARα target gene carnitine palmitoyltransferase 1A (CPT1A), a key enzyme involved in fatty acid β-oxidation, considered an *in vitro* model to study PPARα activation.<sup>22,23</sup> Real-time quantitative PCR (RTqPCR) was employed to assess the effects of the compounds on CPT1A expression. Compounds were tested alone, or in the presence of the potent PPARα agonist GW7647, used as control. As expected, GW7647 robustly stimulated CPT1A expression (Figure 3), whereas compounds 3a–e, 10e, and 13e induced only a weak CPT1A mRNA expression. Notably, the combinations of GW7647 with 3a–e, 10e, or 13e were able to significantly repress CPT1A expression, supporting the antagonistic behavior of the novel compounds on PPARα (Figure 3).


We also explored the potential antiproliferative activity of 3a–e, 10e, and 13e in eight human cancer cell lines representative of four distinct tumor types. We selected three pancreatic (AsPC-1, BxPC-3, Capan-2), two colorectal (HT-29, SW480), two paraganglioma (PTJ64i, PTJ86i), and one renal (A498) cancer cell line, which express PPARα as reported in a previous study,<sup>14</sup> or in the Expression Atlas database (<https://www.ebi.ac.uk/gxa/home>). Preliminary MTT experiments were conducted by treatment of the eight cancer cell lines with 3a–e, 10e, and 13e, with the PPARα antagonist GW6471, or with the PPARα agonist Wy-14,643 for 72 h, at a single concentration (75 μM) (Figure 4).

Overall, Wy-14,643 did not affect cell viability across the tumor cell lines tested (Figure 4), whereas novel compounds,



**Figure 3.** Expression of PPARα target gene CPT1A. Data shown are the means ± SD of three determinations (\**p* < 0.05; \*\**p* < 0.01; \*\*\**p* < 0.001).

as well as GW6471, showed antiproliferative activities, although with variable potency. Notably, all the novel PPARα antagonists had a more marked effect on cell viability in paraganglioma (PGL), as compared to the other cancer cell lines, with inhibition rates in PGL cells ranging from 59% to 98%, in line with the effects obtained with GW6471 in the same cancer cell lines (inhibition rates from 85% to 92%). 3c, 3d, and 10e emerged as the compounds showing more consistent and relevant antiproliferative activities across the eight cancer cell lines, with inhibition rates from 41% to 92% in



**Figure 4.** Effect of compounds on the viability of pancreatic (A), colorectal (B), paraganglioma (C), and renal (D) tumor cell lines. Cell viability was assessed by MTT assay using compounds at 75  $\mu\text{M}$  for 72 h. Data shown are the means  $\pm$  SD of duplicate experiments with quintuplicates determinations. \*Statistically significant differences between control and each compound concentration (\* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ).

the pancreatic cancer cell lines, from 52% to 98% in the colon cancer cell lines, from 84% to 98% in the PGL cell lines, and from 51% to 71% in the renal cancer cell line (Figure 4). Thus, we selected these compounds for further characterization of antiproliferative effects through concentration-dependent experiments.


Pancreatic, colorectal, paraganglioma, and renal cancer cell lines were incubated with 3c, 3d, and 10e for 72 h at concentrations from 0  $\mu\text{M}$  to 24  $\mu\text{M}$  (Figure 5). The treatments significantly reduced cell viability in a concentration-dependent manner, showing variable effects across the tested cancer cell lines. In particular, 3c, 3d, and 10e drastically and significantly decreased paraganglioma cell line viability, as shown by concentration–response curves (Figure 5, panels A, B, C) and cytotoxic concentration ( $CC_{50}$ ) values in the low micromolar range (Figure 5, panel D). Intriguingly, the novel compounds showed greater antiproliferative effects and lower  $CC_{50}$  values than those previously obtained with the reference compound GW6471 in the same paraganglioma cell lines.<sup>14</sup> Remarkably, 3c, 3d, and 10e did not show toxicity against normal HFF-1 fibroblast cells, displaying  $CC_{50}$  values higher than 24  $\mu\text{M}$ , which was the highest concentration used in our MTT assays, and good selectivity index (SI) values (Figure 5, panels A, B, C, D).

Similarly, compounds 3c, 3d, and 10e showed  $CC_{50}$  values higher than 24  $\mu\text{M}$  in pancreatic, colorectal, and renal cancer cell, except 3d that showed a  $CC_{50}$  of 16.99  $\mu\text{M}$  in BxPC-3 and 10e that showed  $CC_{50}$  values of approximately 7  $\mu\text{M}$  in pancreatic and colorectal cancer cell lines and of 4.6  $\mu\text{M}$  in renal cancer cells (Supporting Information, Table S1).


To elucidate the binding mode of this series of compounds and to help interpretation of structure–activity relationship

(SAR) data, we undertook docking studies using the GOLD Suite docking package (CCDC Software Limited: Cambridge, U.K.) with the X-ray crystal structure of PPAR $\alpha$  in complex with the antagonist GW6471 (PDB ID: 1KKQ).<sup>24</sup> In this structure GW6471, bearing an amide headgroup, does not interact with Y464 and pushes the H12 to assume an inactive and less structured conformation. The PPAR LBD is “Y-shaped” and is composed of a polar arm I, which is extended toward H12, a hydrophobic arm II, which is located between H3 and the  $\beta$ -sheet, and a hydrophobic entrance (arm III).

The most potent compounds 3a and 10e were chosen for docking as representative members of benzenesulfonimide derivatives bearing distal phenyldiazenyl and phenylbenzamide moieties, respectively. As illustrated in Figure 6, both compounds adopted a similar U-shaped configuration, wrapping around H3. The oxygen atom of the sulfonimide moiety of 3a (Figures 6A and S2, Supporting Information) was engaged in an H-bond with the OH group of Y314 side chain. Moreover, the phenyl ring of the benzenesulfonimide moiety was optimally oriented for a favorable  $\pi$ – $\pi$  stacking interaction with the Y314 side chain, and the methyl group in *para* formed fruitful hydrophobic interactions with A441. The *gem*-dimethyl substituents were projected into the lipophilic “benzophenone pocket”,<sup>25</sup> making further hydrophobic interactions. The central phenoxy ring also made a  $\pi$ – $\pi$  stacking interaction with the F318 side chain, with the phenoxy oxygen forming a further H-bond with Ne2 of H440. The phenyldiazenyl group was surrounded by sulfur-containing residues such as C275, C276, M355, and M330, forming profitable sulfur–arene interactions.<sup>26</sup> The ligand’s tail fitted well into arm II and positively contributed to overall binding through hydrophobic



**Figure 5.** Compounds **3c**, **3d**, and **10e** affect viability in paraganglioma cancer cell lines with negligible effects on normal fibroblast cells. Concentration–response curves of **3c** (A), **3d** (B), and **10e** (C) on viability of paraganglioma cancer cell lines (PTJ86i and PTJ64i) and of normal fibroblast cells (HFF-1). Cytotoxic effects were tested by MTT assay using compounds at the indicated concentrations for 72 h. Data shown are the means  $\pm$  standard deviation of duplicate experiments with five replicates. Cytotoxic concentration (CC<sub>50</sub>) values are the drug concentrations required to inhibit 50% of cell viability. Selectivity index (SI) values were calculated for each compound as follows: CC<sub>50</sub> on normal fibroblast cells (HFF-1)/CC<sub>50</sub> on cancer cells (D). \*Statistically significant differences between control and each compound concentration (\* $p$  < 0.05; \*\*\* $p$  < 0.001).



**Figure 6.** Binding mode of compounds **3a** (A, yellow sticks) and **10e** (B, violet sticks) in PPAR $\alpha$  LBD represented as green ribbon model. Only amino acids located within 4 Å of the bound ligand are displayed (white sticks) and labeled. H-bonds discussed in the text are depicted as dashed black lines.

contacts with residues I272 of H3, L254 and L247 of H2', and I241, I339, V332 of the  $\beta$ -sheet.

By looking at the binding mode of compound **10e** (Figures 6B and S3, Supporting Information), it was observed that an H-bond was also formed, through its carbonyl oxygen, with the OH group of the Y314 side chain, whereas the aromatic ring of the benzenesulfonamide moiety made hydrophobic interac-

tions with V444 and F273. In addition, the central phenoxy ring was engaged in an edge-to-face  $\pi$ – $\pi$  stacking interaction with the H440 side chain. The phenylbenzamide moiety, besides the hydrophobic contacts observed for **3a**, formed two additional H-bonds with the T279 OH group and the NH backbone of A333 on the  $\beta$ -sheet.

The overlay of the docked pose of **3a** and **10e** with the X-ray crystal pose of the PPAR $\alpha$  antagonist GW6471 (Supporting Information, Figure S4A) revealed a similar binding mode, with analogous positioning of head groups and a similar orientation of the hydrophobic tail groups. Noteworthy, the benzenesulfonamide headgroup of **3a** and **10e** projected into an area that is usually occupied by the side chain of Y464 in PPAR $\alpha$  LBD bound to agonist ligands, such as GW409544 (Supporting Information, Figure S4B).<sup>27</sup> Thus, the benzenesulfonamide derivatives do not interact with this residue that is critical for receptor activation due to steric hindrance, likely forcing H12 out of the agonist bound position and inducing a PPAR $\alpha$  LBD conformation that interacts efficiently with corepressors.

Docking studies allowed deriving some clues about SAR. As regards derivatives **3a–g**, when the methyl group at position *para* of **3a** was replaced with methoxy (**3b**) or chlorine (**3c**), the IC<sub>50</sub> remained in the low micromolar range, suggesting that these compounds are able to form the same favorable interactions observed for **3a**. Thus, the *para* position of the benzenesulfonimide moiety requires substituents with a certain degree of lipophilicity, but quite limited in size. In fact, the insertion of the more hydrophilic nitro group (**3d**), or the bulkier methylamide group (**3e**), caused a slight decrease in potency; for derivatives **3f** and **3g**, a further drop in PPAR $\alpha$  antagonistic activity was observed, produced by the impaired accommodation of an additional aromatic ring into arm I of PPAR $\alpha$ . The overlay of the docked poses of **3a** and **3g** (Figure S5A, Supporting Information) revealed that the benzyl amide substituent was shifted upward in arm I and dramatically altered the interactions pattern of the benzenesulfonimide group. Derivatives **4a–d**, bearing the amide headgroup and phenyldiazanyl tail group, turned out to be less active because of the loss of profitable H-bonds and  $\pi$ – $\pi$  stacking interactions with Y314 observed in docking experiments. On comparing the docked pose of **3a** and **4c** (Figure S5B, Supporting Information), it is clear that, despite a similar positioning of the phenyldiazanyl tail, the amide moiety was not properly oriented to engage an H bond with Y314. Also for derivatives **10a–e**, the presence of the benzenesulfonamide group was critical for the antagonistic activity, as only derivative **10e** displayed an IC<sub>50</sub> in the low micromolar range. From the docked pose of **10e**, it can be argued that the primary amide (**10a**) was no longer able to form the hydrophobic interactions with residues V444 and F273, whereas both aliphatic (**10b**) and aromatic groups (**10c** and **10d**) could not be placed at an optimal distance to favorably interact with such residues. As shown in Figure S5C, the phenylbenzamide tails of both **10e** and **10b** displayed the same orientation; however, the butyl amide headgroup of **10b** could not properly interact with Y314, but instead was oriented toward Q277. Thus, the weak interactions formed by the headgroup were unable to induce an antagonistic conformation. This might account for the slight receptor activation and, in turn, the low antagonistic activity shown by derivatives **10a–d**. For derivatives **13a–e**, the presence of the urea moiety at the tail group improved the antagonistic activity (see **13a** and **13b**) due to its propensity to extend more deeply into arm II and to make an H-bond with the C275 backbone. However, introduction of phenyl and benzyl substituents (**13c** and **13d**) on the amide headgroup introduced steric restrictions, making it more difficult for the ligands to interact with Y314 and with the hydrophobic residues A441, V444, and F273. Again, the introduction of the

benzenesulfonamide group increased potency (**13e**). As shown in Figure S5D, this moiety well anchored the ligand into arm I in a similar fashion to **10e**. The presence of the sulfonyl group avoids the steric restrictions by rotation of the phenyl ring to a position that is better suited to interact with hydrophobic residues. Thus, the benzenesulfonamide moiety is a key structural feature in this series of derivatives to confer antagonistic activity.

In conclusion, this study led to the identification of novel sulfonimide and amide PPAR $\alpha$  antagonists. Most potent compounds induced marked antiproliferative activity when tested in *in vitro* cancer cells expressing PPAR $\alpha$  (pancreatic, colorectal, paraganglioma, and renal cancer cell lines). In addition, binding modes of representative benzenesulfonimide derivatives **3a** and **10e** helped to rationalize results from transactivation assay and give information about SAR of this class of compounds.

## ■ ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsmchemlett.9b00666>.

Experimental procedures, full characterization of compounds, 2D ligand-interaction diagrams of compounds into the PPAR binding pocket, NMR spectra (PDF)

## ■ AUTHOR INFORMATION

### Corresponding Author

Alessandra Ammazalorso – Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, 66100 Chieti, Italy; [orcid.org/0000-0003-4369-1772](https://orcid.org/0000-0003-4369-1772); Phone: +39 0871 3554682; Email: [alessandra.ammazzalorso@unich.it](mailto:alessandra.ammazzalorso@unich.it)

### Authors

- Isabella Bruno – Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, 66100 Chieti, Italy  
Rosalba Florio – Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, 66100 Chieti, Italy  
Laura De Lellis – Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, 66100 Chieti, Italy  
Antonio Laghezza – Department of Pharmacy-Drug Science, University of Bari “Aldo Moro”, 70126 Bari, Italy; [orcid.org/0000-0001-6221-6155](https://orcid.org/0000-0001-6221-6155)  
Carmen Cerchia – Department of Pharmacy, “Drug Discovery” Laboratory, University of Napoli “Federico II”, 80131 Napoli, Italy  
Barbara De Filippis – Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, 66100 Chieti, Italy  
Marialuigia Fantacuzzi – Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, 66100 Chieti, Italy  
Letizia Giampietro – Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, 66100 Chieti, Italy; [orcid.org/0000-0002-8483-1885](https://orcid.org/0000-0002-8483-1885)  
Cristina Maccallini – Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, 66100 Chieti, Italy; [orcid.org/0000-0003-2957-8650](https://orcid.org/0000-0003-2957-8650)  
Paolo Tortorella – Department of Pharmacy-Drug Science, University of Bari “Aldo Moro”, 70126 Bari, Italy; [orcid.org/0000-0003-1358-7376](https://orcid.org/0000-0003-1358-7376)  
Serena Veschi – Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, 66100 Chieti, Italy

Fulvio Liodice – Department of Pharmacy-Drug Science, University of Bari “Aldo Moro”, 70126 Bari, Italy;

orcid.org/0000-0003-3384-574X

Antonio Lavecchia – Department of Pharmacy, “Drug Discovery” Laboratory, University of Napoli “Federico II”, 80131 Napoli, Italy; orcid.org/0000-0002-2181-8026

Alessandro Cama – Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, 66100 Chieti, Italy; Center for Advanced Studies and Technology CAST, 66100 Chieti, Italy

Rosa Amoroso – Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, 66100 Chieti, Italy

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acsmchemlett.9b00666>

## Funding

This work was supported by FAR funds (Italian Ministry for Instruction, University and Research) assigned to A.A. The study was also supported by the Ministry of Education, University and Research (MIUR), Progetti di Ricerca di Interesse Nazionale (PRIN) funds (Grant Number 2017EKMFTN\_005), assigned to A.C.

## Notes

The authors declare no competing financial interest.

## Biography

Alessandra Ammazalorso received her Ph.D. from the G. d’Annunzio University, Chieti-Pescara, Italy, in 2001. She is currently an Assistant Professor at Pharmacy Department, University of Chieti-Pescara. Her research interests include the design and synthesis of small-molecule drugs, mainly PPAR ligands and enzymatic inhibitors of nitric oxide synthases and aromatase. The results of these studies have been published in over 60 papers.

## ABBREVIATIONS

PPARs, Peroxisome Proliferator-Activated Receptors; TZDs, thiazolidinediones; FAO, fatty acid oxidation; EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; DMAP, 4-dimethylaminopyridine; LBD, ligand binding domain; DCC, *N,N'*-dicyclohexylcarbodiimide; HOBt, 1-hydroxybenzotriazole hydrate; NMM, *N*-methylmorpholine; TEA, triethylamine; DIAD, diisopropyl azodicarboxylate; CPT1A, carnitine palmitoyltransferase 1A; RTqPCR, real-time quantitative PCR; PGL, paraganglioma; CC<sub>50</sub>, median cytotoxic concentration.

## REFERENCES

- (1) Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. *Nature* **1990**, *347*, 645–650.
- (2) Berger, J. P.; Akiyama, T. E.; Meinke, P. T. PPARs: therapeutic targets for metabolic disease. *Trends Pharmacol. Sci.* **2005**, *26*, 244–251.
- (3) Staels, B.; Dallongeville, J.; Auwerx, J.; Schoonjans, K.; Leitersdorf, E.; Fruchart, J.-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. *Circulation* **1998**, *98*, 2088–2093.
- (4) Katsiki, N.; Nikolic, D.; Montalto, G.; Banach, M.; Mikhailidis, D. P.; Rizzo, M. The role of fibrate treatment in dyslipidemia: an overview. *Curr. Pharm. Des.* **2013**, *19*, 3124–3131.
- (5) Sarafidis, P. A. Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update. *Fundam. Clin. Pharmacol.* **2008**, *22*, 247–264.
- (6) Ammazalorso, A.; De Filippis, B.; Giampietro, L.; Amoroso, R. Blocking the Peroxisome Proliferator-Activated Receptor (PPAR): an overview. *ChemMedChem* **2013**, *8*, 1609–1616.

(7) Hashimoto, Y.; Miyachi, H. Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis. *Bioorg. Med. Chem.* **2005**, *13*, 5080–5093.

(8) Samudio, I.; Fiegl, M.; Andreeff, M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. *Cancer Res.* **2009**, *69*, 2163–2166.

(9) De Lellis, L.; Cimini, A.; Veschi, S.; Benedetti, E.; Amoroso, R.; Cama, A.; Ammazalorso, A. The anticancer potential of Peroxisome Proliferator-Activated Receptor antagonists. *ChemMedChem* **2018**, *13*, 209–219.

(10) Messmer, D.; Lorrain, K.; Stebbins, K.; Bravo, Y.; Stock, N.; Cabrera, G.; Correa, L.; Chen, A.; Jacintho, J.; Chiorazzi, N.; Yan, X. J.; Spaner, D.; Prasit, P.; Lorrain, D. A selective novel Peroxisome Proliferator-Activated Receptor (PPAR)- $\alpha$  antagonist induces apoptosis and inhibits proliferation of CLL cells in vitro and in vivo. *Mol. Med.* **2015**, *21*, 410–419.

(11) Abu Aboud, O.; Donohoe, D.; Bultman, S.; Fitch, M.; Riiff, T.; Hellerstein, M.; Weiss, R. H. PPAR $\alpha$  inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth. *Am. J. Physiol. Cell. Physiol.* **2015**, *308*, C890–C898.

(12) Benedetti, E.; d’Angelo, M.; Ammazalorso, A.; Gravina, G.; Laezza, C.; Antonosante, A.; Panella, G.; Cinque, B.; Cristiano, L.; Dhez, A. C.; Astarita, C.; Galzio, R.; Cifone, M. G.; Ippoliti, R.; Amoroso, R.; Di Cesare, E.; Giordano, A.; Cimini, A. PPAR $\alpha$  antagonist AA452 triggers metabolic reprogramming and increases sensitivity to radiation therapy in human glioblastoma primary cells. *J. Cell. Physiol.* **2017**, *232*, 1458–1466.

(13) Ammazalorso, A.; De Lellis, L.; Florio, R.; Bruno, I.; De Filippis, B.; Fantacuzzi, M.; Giampietro, L.; Maccallini, C.; Perconti, S.; Verginelli, F.; Cama, A.; Amoroso, R. Cytotoxic effect of a family of Peroxisome Proliferator-Activated Receptor antagonists in colorectal and pancreatic cancer cell lines. *Chem. Biol. Drug Des.* **2017**, *90*, 1029–1035.

(14) Florio, R.; De Lellis, L.; di Giacomo, V.; Di Marcantonio, M. C.; Cristiano, L.; Basile, M.; Verginelli, F.; Verzilli, D.; Ammazalorso, A.; Prasad, S. C.; Cataldi, A.; Sanna, M.; Cimini, A.; Mariani-Costantini, R.; Mincione, G.; Cama, A. Effects of PPAR $\alpha$  inhibition in head and neck paraganglioma cells. *PLoS One* **2017**, *12* (6), No. e0178995.

(15) Ammazalorso, A.; De Lellis, L.; Florio, R.; Laghezza, A.; De Filippis, B.; Fantacuzzi, M.; Giampietro, L.; Maccallini, C.; Tortorella, P.; Veschi, S.; Liodice, F.; Cama, A.; Amoroso, R. Synthesis of novel benzothiazole amides: evaluation of PPAR activity and anti-proliferative effects in paraganglioma, pancreatic and colorectal cancer cell lines. *Bioorg. Med. Chem. Lett.* **2019**, *29*, 2302–2306.

(16) Ammazalorso, A.; Giancristofaro, A.; D’Angelo, A.; De Filippis, B.; Fantacuzzi, M.; Giampietro, L.; Maccallini, C.; Amoroso, R. Benzothiazole-based *N*-(phenylsulfonyl)amides as a novel family of PPAR $\alpha$  antagonists. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 4869–4872.

(17) Ammazalorso, A.; D’Angelo, A.; Giancristofaro, A.; De Filippis, B.; Di Matteo, M.; Fantacuzzi, M.; Giampietro, L.; Linciano, P.; Maccallini, C.; Amoroso, R. Fibrate-derived *N*-(methylsulfonyl)amides with antagonistic properties on PPAR $\alpha$ . *Eur. J. Med. Chem.* **2012**, *58*, 317–322.

(18) De Filippis, B.; Giancristofaro, A.; Ammazalorso, A.; D’Angelo, A.; Fantacuzzi, M.; Giampietro, L.; Maccallini, C.; Petruzzelli, M.; Amoroso, R. Discovery of gemfibrozil analogues that activate PPAR $\alpha$  and enhance the expression of gene CPT1A involved in fatty acids catabolism. *Eur. J. Med. Chem.* **2011**, *46*, 5218–5224.

(19) Giampietro, L.; D’Angelo, A.; Giancristofaro, A.; Ammazalorso, A.; De Filippis, B.; Fantacuzzi, M.; Linciano, P.; Maccallini, C.; Amoroso, R. Synthesis and structure-activity relationships of fibrate-based analogues inside PPARs. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 7662–7666.

(20) Pinelli, A.; Godio, C.; Laghezza, A.; Mitro, N.; Fracchiolla, G.; Tortorella, V.; Lavecchia, A.; Novellino, E.; Fruchart, J. C.; Staels, B.; Crestani, M.; Liodice, F. Synthesis, biological evaluation, and

molecular modeling investigation of new chiral fibrates with PPAR $\alpha$  and PPAR $\gamma$  agonist activity. *J. Med. Chem.* **2005**, *48*, 5509–5519.

(21) Porcelli, L.; Gilardi, F.; Laghezza, A.; Piemontese, L.; Mitro, N.; Azzariti, A.; Altieri, F.; Cervoni, L.; Fracchiolla, G.; Giudici, M.; Guerrini, U.; Lavecchia, A.; Montanari, R.; Di Giovanni, C.; Paradiso, A.; Pochetti, G.; Simone, G. M.; Tortorella, P.; Crestani, M.; Loiodice, F. Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity. *J. Med. Chem.* **2012**, *55*, 37–54.

(22) Ammazalorso, A.; Carrieri, A.; Verginelli, F.; Bruno, I.; Carbonara, G.; D'Angelo, A.; De Filippis, B.; Fantacuzzi, M.; Florio, R.; Fracchiolla, G.; Giampietro, L.; Giancristofaro, A.; Maccallini, C.; Cama, A.; Amoroso, R. Synthesis, in vitro evaluation, and molecular modeling investigation of benzenesulfonimide Peroxisome Proliferator-Activated Receptors  $\alpha$  antagonists. *Eur. J. Med. Chem.* **2016**, *114*, 191–200.

(23) Giampietro, L.; Laghezza, A.; Cerchia, C.; Florio, R.; Recinella, L.; Capone, F.; Ammazalorso, A.; Bruno, I.; De Filippis, B.; Fantacuzzi, M.; Ferrante, C.; Maccallini, C.; Tortorella, P.; Verginelli, F.; Brunetti, L.; Cama, A.; Amoroso, R.; Loiodice, F.; Lavecchia, A. Novel phenyldiazanyl fibrate analogues as PPAR $\alpha/\gamma/\delta$  pan-agonists for the amelioration of metabolic syndrome. *ACS Med. Chem. Lett.* **2019**, *10*, 545–551.

(24) Xu, H. E.; Stanley, T. B.; Montana, V. G.; Lambert, M. H.; Shearer, B. G.; Cobb, J. E.; McKee, D. D.; Galardi, C. M.; Plunket, K.; Nolte, R. T.; Parks, D. J.; Moore, J. T.; Kliewer, S. A.; Willson, T. M.; Stimmel, J. B. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPAR $\alpha$ . *Nature* **2002**, *415*, 813–817.

(25) Gampe, R. T., Jr; Montana, V. G.; Lambert, M. H.; Miller, A. B.; Bledsoe, R. K.; Milburn, M. V.; Kliewer, S. A.; Willson, T. M.; Xu, H. E. Asymmetry in the PPAR $\gamma$ /RXR $\alpha$  crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. *Mol. Cell* **2000**, *5*, 545–555.

(26) Forbes, C. R.; Sinha, S. K.; Ganguly, H. K.; Bai, S.; Yap, G. P. A.; Patel, S.; Zondlo, N. J. Insights into thiol-aromatic interactions: a stereoelectronic basis for S-H/ $\pi$  interactions. *J. Am. Chem. Soc.* **2017**, *139*, 1842–1855.

(27) Xu, H. E.; Lambert, M. H.; Montana, V. G.; Plunket, K. D.; Moore, L. B.; Collins, J. L.; Oplinger, J. A.; Kliewer, S. A.; Gampe, R. T., Jr.; McKee, D. D.; Moore, J. T.; Willson, T. M. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. *Proc. Natl. Acad. Sci. U. S. A.* **2001**, *98*, 13919–13924.